BridgeBio Oncology Therapeutics is set to go public through a SPAC merger with Helix Acquisition Corp. II. The deal will garner over $450m to support clinical tests of three drug candidates. BridgeBio Oncology plans to improve the treatment of RAS, cancer-causing proteins. The company is also working on a drug that targets KRAS G12C in both “on” and “off” states. Preliminary data for this drug is expected in 2025.
Top 10 EdTech News Stories of February 2025
PowerSchool, a major US student information system provider, confirmed a data breach affecting millions of students. A stolen password led to unauthorized access, revealing names,
